Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

Not Recruiting

Trial ID: NCT00568308


The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

Official Title

A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma

Stanford Investigator(s)

Samuel So, MD
Samuel So, MD

Lui Hac Minh Professor in the School of Medicine


Key Inclusion Criteria:

   - Histologically-proven primary hepatocellular carcinoma with curative resection
   performed in the 4 - 6 weeks prior to randomisation.

   - ECOG performance status 0 to 2

   - Child Pugh classification A or B

Key Exclusion Criteria:

   - Any evidence of tumour metastasis or co-existing malignant disease

   - Any prior recurrence of HCC or any liver resection prior to the most recent procedure

   - History of prior HCC therapy


drug: placebo

drug: PI-88

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kerry Hsieh

New Trial Alerts